December 06, 2016
Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
December 05, 2016
Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
November 28, 2016
Kadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 19, 2016
Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
November 14, 2016
Kadmon to Present at the Jefferies 2016 London Healthcare Conference
November 09, 2016
Kadmon Provides Business Update and Reports Third Quarter 2016 Financial Results
October 17, 2016
Kadmon to Present at the 15th Annual BIO Investor Forum
September 21, 2016
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
September 07, 2016
Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016
Learn more about investing in our growth.
Receive press releases, SEC filings and more.
Subscribe to alerts
Kadmon Corporation, LLC
Copyright 2017. All Rights Reserved.